Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes ...
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, focused on developing novel therapeutics for cancer patients. The company's mission is to create treatments that reverse the inhibitory effects of cancer on the immune system, addressing critical challenges in oncology such as drug resistance and immune ...Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, focused on developing novel therapeutics for cancer patients. The company's mission is to create treatments that reverse the inhibitory effects of cancer on the immune system, addressing critical challenges in oncology such as drug resistance and immune suppression. Initially incorporated in 2013 under the name NanoGB13, Inc., the company was renamed Kairos Pharma in July 2016. The company went public in September 2024, listing on the NYSE American under the symbol KAPA. Kairos Pharma's therapeutic portfolio includes antibodies and small molecules targeting various malignancies, including prostate, lung, and breast cancer, as well as glioblastoma. The company leverages structural biology to design therapies that overcome resistance mechanisms, aiming to restore the body's immune response against tumors. Key leadership includes CEO and Chairman John S. Yu, who is also a neurosurgeon, along with CFO Doug Samuelson, VP of R&D Ramchandran Murali, and Chief Scientific Officer Neil Bhowmick. The company has a small team of approximately 4 employees, reflecting its early-stage nature. As a clinical-stage company, Kairos Pharma has not yet generated revenue, reporting zero revenue and negative net income, with a market cap of around $7.6 million. The company's financials show negative free cash flow and an enterprise value of approximately $5 million, indicating ongoing investment in research and development. Despite its small size, Kairos Pharma aims to make a significant impact in the oncology space by focusing on innovative approaches to overcome drug resistance and enhance immune response, ultimately improving outcomes for cancer patients.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-5.4M
-109.3%
+16.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-3.4M
+13.0%
+2.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
27.07x
+544.1%
+16.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
